“Brake” and “accelerator”: revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy
Targeted anti-angiogenic therapies against vascular endothelial growth factor (VEGF) are standard treatments for various advanced cancers. However, their clinical benefits are often limited by acquired resistance, with some patients even exhibiting par…